Stock Financial Ratios, Dividends, Split History
MHLA / Maiden Holdings Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||1,704.14|
|Enterprise Value ($M)||1,891.16|
|Book Value / Share||14.84|
|Price / Book||1.37|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Weighted Average Number Of Diluted Shares Outstanding||85,678,232|
|Common Shares Outstanding||83,007,351|
|Weighted Average Number Of Shares Outstanding Basic||85,678,232|
|Common Stock Shares Outstanding||82,974,895|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-0.11|
|Return on Assets (ROA)||-0.03|
|Return on Equity (ROE)||-0.12|
|Income Statement (mra) ($M)|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||458.53|
|Cash from Investing||-378.89|
|Cash from Financing||-378.89|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1412100|
|G5753U120 0G573U112 036419750 G5753U952|
|SIC 6331 - Fire, Marine, and Casualty Insurance|
Stock splits are used by Maiden Holdings Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
Related News Stories
The company was affected by deteriorated underwriting margins and reported a combined ratio of 101.8% vs. 100.9% one-year ago. (2-0)
Keryx Biopharmaceuticals Inc. (KERX - Free Report) reported a loss of 18 cents per share in the first quarter of 2018, narrower than Zacks Consensus Estimate of a loss of 19 cents. The loss was also narrower than the year-ago loss of 21 cents. (58-0)
Maiden Holdings, Ltd. (MHLD - Free Report) reported earnings per share of 20 cents in the first quarter of 2018, which declined 23% year over year. (35-0)
Good morning, ladies and gentlemen, and welcome to the Maiden Holdings' First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. (2-0)
Perhaps the most important thing in the past month for the fixed income investors was that the $TNX passed 3.00% for the first time since 2014. Adding the constant uptrend in the 3-month LIBOR rate, the pressure over the preferred stocks and baby bonds started to rise. Still, we do not observe any severe sell-off but the whole segment is experiencing some weakness. (2-0)
as of ET